Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations.

ABSTRACT: Human Immunodeficiency Virus 1 (HIV-1) evades adaptive immunity by means of its extremely high mutation rate, which allows the HIV envelope glycoprotein to continuously escape from the action of antibodies. However, some broadly neutralizing antibodies (bNAbs) targeting specific viral regions show the ability to block the infectivity of a large number of viral variants. The discovery of these antibodies opens new avenues in anti-HIV therapy; however, they are still suboptimal tools as their amplitude of action ranges between 50% and 90% of viral variants. In this context, being able to discriminate between sensitive and resistant strains to an antibody would be of great interest for the design of optimal clinical antibody treatments and to engineer potent bNAbs for clinical use. Here, we d

SUBMITTER: Amengual-Rigo P 

PROVIDER: S-EPMC7602999 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature